Karlsson Rose-Marie, Tanaka Kohichi, Saksida Lisa M, Bussey Timothy J, Heilig Markus, Holmes Andrew
Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, NIH, 10-Center Drive, 10 Room 1E-5330, Bethesda, MD 20892, USA.
Neuropsychopharmacology. 2009 May;34(6):1578-89. doi: 10.1038/npp.2008.215. Epub 2008 Dec 10.
Glutamatergic dysfunction is increasingly implicated in the pathophysiology of schizophrenia. Current models postulate that dysfunction of glutamate and its receptors underlie many of the symptoms in this disease. However, the mechanisms involved are not well understood. Although elucidating the role for glutamate transporters in the disease has been limited by the absence of pharmacological tools that selectively target the transporter, we recently showed that glial glutamate and aspartate transporter (GLAST; excitatory amino-acid transporter 1) mutant mice exhibit abnormalities on behavioral measures thought to model the positive symptoms of schizophrenia, some of which were rescued by treatment with either haloperidol or the mGlu2/3 agonist, LY379268 the mGlu2/3 agonist, LY379268. To further determine the role of GLAST in schizophrenia-related behaviors we tested GLAST mutant mice on a series of behavioral paradigms associated with the negative (social withdrawal, anhedonia), sensorimotor gating (prepulse inhibition of startle), and executive/cognitive (discrimination learning, extinction) symptoms of schizophrenia. GLAST knockout (KO) mice showed poor nesting behavior and abnormal sociability, whereas KO and heterozygous (HET) both demonstrated lesser preference for a novel social stimulus compared to wild-type littermate controls. GLAST KO, but not HET, had a significantly reduced acoustic startle response, but no significant deficit in prepulse inhibition of startle. GLAST KO and HET showed normal sucrose preference. In an instrumental visual discrimination task, KO showed impaired learning. By contrast, acquisition and extinction of a simple instrumental response was normal. The mGlu2/3 agonist, LY379268, failed to rescue the discrimination impairment in KO mice. These findings demonstrate that gene deletion of GLAST produces select phenotypic abnormalities related to the negative and cognitive symptoms of schizophrenia.
谷氨酸能功能障碍在精神分裂症的病理生理学中所起的作用越来越受到关注。目前的模型假定,谷氨酸及其受体功能障碍是该疾病许多症状的基础。然而,其中涉及的机制尚未完全明确。尽管由于缺乏选择性作用于转运体的药理学工具,关于谷氨酸转运体在该疾病中的作用的研究受到限制,但我们最近发现,胶质细胞谷氨酸和天冬氨酸转运体(GLAST;兴奋性氨基酸转运体1)突变小鼠在被认为可模拟精神分裂症阳性症状的行为测试中表现出异常,其中一些异常可通过使用氟哌啶醇或mGlu2/3激动剂LY379268得到改善。为了进一步确定GLAST在精神分裂症相关行为中的作用,我们在一系列与精神分裂症的阴性症状(社交退缩、快感缺失)、感觉运动门控(惊吓前脉冲抑制)以及执行/认知症状(辨别学习、消退)相关的行为范式中对GLAST突变小鼠进行了测试。GLAST基因敲除(KO)小鼠表现出筑巢行为不佳和社交能力异常,而KO和杂合子(HET)小鼠与野生型同窝对照相比,对新的社交刺激的偏好均较低。GLAST KO小鼠而非HET小鼠的听觉惊吓反应显著降低,但惊吓前脉冲抑制无明显缺陷。GLAST KO和HET小鼠的蔗糖偏好正常。在一项工具性视觉辨别任务中,KO小鼠表现出学习障碍。相比之下,简单工具性反应的习得和消退则正常。mGlu2/3激动剂LY379268未能挽救KO小鼠的辨别障碍。这些发现表明,GLAST基因缺失会导致与精神分裂症阴性和认知症状相关的特定表型异常。